ATS Corporation’s second-quarter adjusted EPS was C$0.27, below the C$0.33 estimate. Lower revenue and weaker margins weighed on results. But orders grew year over year, led by life sciences.
ATS Corporation (TSX: ATS) reported its second-quarter fiscal 2027 results on November 4, 2026. Adjusted basic EPS came in at C$0.27, 18.2% below the calendar estimate of C$0.33. Revenue fell 8.6% from a year earlier to C$665.8 million, and adjusted EBITDA dropped to C$80.7 million from C$103.7 million.
Recent earnings trend
ATS CORP
ATS.TO
ATS.TO
ATS CORP
WealthAwesomeMarket cap
$2.41B
P/E
51.2x
52W high
$49.48
52W low
$23.84
1W change
-8.25%
Beta
1.18
Analyst Price Targets
Based on analyst covering ATS · as of Oct 19, 2026
Wall Street analysts forecast ATS stock price to rise 50.7% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$37.05
+50.7% Upside
Previously C$37.30 on Oct 1, 2026
Current Price
C$24.59
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ATS's historical volatility
30-Day Vol
34.3%
Annualized
90-Day Vol
62.4%
Annualized
Trend (90d)
-47.1%
Annualized drift
90d Mean
C$20.78
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$23.25 | C$20.65 – C$26.17 |
| 60 trading days | C$21.98 | C$18.59 – C$25.99 |
| 90 trading days | C$20.78 | C$16.93 – C$25.51 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Analyst coverage: 8 analyst(s) cover this name; upcoming EPS consensus is available.
Beat estimates in 1 of the last 4 comparable quarter(s).
| Fiscal period | Report date | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| 2026-12-31 | 2027-02-03 | — | 0.4000 | — |
| 2026-09-30 | 2026-11-04 | 0.2700 | 0.3300 | -18.2% |
| 2026-06-30 | 2026-08-06 | 0.3500 | 0.4200 | -16.7% |
| 2026-03-31 | 2026-05-28 | 0.3600 | 0.4400 | -18.2% |
| 2025-12-31 | 2026-02-04 | 0.4800 | 0.4400 | +9.1% |
| 2025-09-30 | 2025-11-05 | 0.4500 | 0.4300 | +4.7% |
There was a brighter sign: order bookings rose 12.7% year over year to C$827 million. Life sciences bookings reached their highest level since fiscal Q2 2025.
Investor takeaway: ATS is under near-term pressure from lower volumes, a weaker sales mix and delayed orders outside life sciences. Stronger bookings and demand in life sciences offer a more positive signal, but the company still needs to turn those orders into revenue and improve margins. Follow ATS.TO results and updates on the ATS stock page.
C$827 million in quarterly order bookings
Bookings rose 12.7% from a year earlier and 26.1% from the previous quarter, despite the earnings miss. Life sciences led the increase. ATS said delays in bookings outside that segment added to near-term pressure. The key question is whether the stronger orders lead to higher revenue and better margins.
Bull case
Bookings increased both year over year and from the previous quarter, while the life sciences backlog reached a record. Management also cited momentum in radiopharmaceuticals and nuclear markets, growth in service revenue and a fixed-cost transformation program. If ATS converts bookings into revenue and improves execution, these factors could help restore growth and returns.
Bear case
Revenue, adjusted EBITDA and adjusted EPS all fell from a year earlier, and ATS reported a C$5.0 million net loss. Adjusted operating margin narrowed to 8.6% from 10.9%, as lower volumes and a weaker sales mix weighed on results. Delayed orders outside life sciences, including in packaging automation, add uncertainty. ATS has also missed EPS estimates in three of its past four reported quarters.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
